Market closed
Verrica Pharmaceuticals/$VRCA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Ticker
$VRCA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
100
Website
VRCA Metrics
BasicAdvanced
$45M
Market cap
-
P/E ratio
-$1.83
EPS
1.46
Beta
-
Dividend rate
Price and volume
Market cap
$45M
Beta
1.46
52-week high
$11.41
52-week low
$0.70
Average daily volume
723K
Financial strength
Current ratio
1.341
Quick ratio
1.096
Long term debt to equity
-134.951
Total debt to equity
-138.36
Interest coverage (TTM)
-7.93%
Management effectiveness
Return on assets (TTM)
-72.18%
Return on equity (TTM)
-2,059.89%
Valuation
Price to revenue (TTM)
5.001
Price to book
-1.33
Price to tangible book (TTM)
-1.33
Price to free cash flow (TTM)
-0.773
Growth
Revenue change (TTM)
187.45%
Earnings per share change (TTM)
66.30%
3-year revenue growth (CAGR)
-8.44%
3-year earnings per share growth (CAGR)
7.87%
What the Analysts think about VRCA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Verrica Pharmaceuticals stock.
VRCA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VRCA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VRCA News
AllArticlesVideos
Verrica Announces Pricing of $42.0 Million Public Offering
GlobeNewsWire·2 days ago
Verrica Announces Proposed Public Offering
GlobeNewsWire·2 days ago
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Verrica Pharmaceuticals stock?
Verrica Pharmaceuticals (VRCA) has a market cap of $45M as of November 23, 2024.
What is the P/E ratio for Verrica Pharmaceuticals stock?
The price to earnings (P/E) ratio for Verrica Pharmaceuticals (VRCA) stock is 0 as of November 23, 2024.
Does Verrica Pharmaceuticals stock pay dividends?
No, Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next Verrica Pharmaceuticals dividend payment date?
Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders.
What is the beta indicator for Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.